Valneva Stock: Shares Surge Following Announcement of 2025 Annual Revenue
Valneva's stock saw a significant increase this Thursday, driven by the release of its preliminary results for the fiscal year 2025. The stock rose by 4.67% to 4.844 euros mid-session, breaking past its previous resistance level at 4.63 euros. Over the week, the performance has reached nearly 19.3%.
The biopharmaceutical group Valneva unveiled on February 19 its preliminary results for the fiscal year 2025, reporting a revenue of 174.7 million euros, consistent with the previous year. The company also reported a strengthened cash position, a key element for funding its upcoming development stages. Focus now shifts to 2026, a year described as decisive by the management. Initial Phase 3 results of the Lyme disease vaccine candidate, developed in partnership with Pfizer, are expected in the coming months. The presentation of the complete annual results is scheduled for March 16, followed by the first quarter accounts on May 7.
Technical Breakthrough in Today's Session
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Today's session marks a significant technical event: Valneva's stock price has surpassed the resistance level at 4.63 euros, which was the upper limit of the Bollinger Bands. This breakthrough follows a weekly rally of nearly 19.3%, bringing the three-month gain to 28.2% and the annual increase to 34.6%. The RSI, an indicator measuring the rate of price change, is at 75, above the commonly regarded overbought threshold of 70. This level reflects the intensity of the recent movement, yet does not alone signal a reversal. The stock is now trading well above its 50-day and 200-day moving averages, positioned at 4.01 and 3.66 euros respectively, confirming the bullish trend established over several weeks.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
